


On the Origin of Bacterial Resistance to Penicillin: Comparison of a β -Lactamase and a Penicillin Target

J. A. KELLY,* O. DIDEBERG, P. CHARLIER, J. P. WERY, M. LIBERT, P. C. MOEWS, J. R. KNOX, C. DUEZ, CL. FRAIPONT, B. JORIS, J. DUSART, J. M. FRÈRE, J. M. GHUYSEN

Structural data are now available for comparing a penicillin target enzyme, the D-alanyl-D-alanine-peptidase from *Streptomyces* R61, with a penicillin-hydrolyzing enzyme, the β -lactamase from *Bacillus licheniformis* 749/C. Although the two enzymes have distinct catalytic properties and lack relatedness in their overall amino acid sequences except near the active-site serine, the significant similarity found by x-ray crystallography in the spatial arrangement of the elements of secondary structure provides strong support for earlier hypotheses that β -lactamases arose from penicillin-sensitive D-alanyl-D-alanine-peptidases involved in bacterial wall peptidoglycan metabolism.

SINCE THE FIRST CURES ACHIEVED BY penicillin in 1941, an expanding family of β -lactam antibiotics has been developed to combat bacteria. As a result of gene transfer and recombination, an increasing number of bacterial species produce β -lactamases, enzymes that rapidly transform β -lactams into inactive metabolites by hydrolyzing the β -lactam bond:



The origin of the genes coding for β -lactamases has been much debated. In 1965, Tipper and Strominger proposed that β -lactamases might have arisen from an essential, penicillin-sensitive D-alanyl-D-alanine-cleaving peptidase (hereafter DD-peptidase) involved in the last stages of the bacterial wall peptidoglycan synthesis (1, 2). These cell wall synthetic enzymes are the targets of β -lactams (3). Others in the field have expressed doubt, however, that there is convincing evidence for common ancestry (4, 5).

All bacteria contain an assortment of membrane-bound penicillin-binding proteins (PBP's) that are related to such distinct cellular functions as elongation and septation. These proteins do not have the same degree of "essentiality" and show various amounts of sensitivity to β -lactam antibiotics. In spite of this diversity, the PBP's to

which catalytic activity could be assigned have an active-site serine and function as DD-peptidases (3, 6). They catalyze transpeptidation reactions involving the COOH-terminal D-alanyl-D-alanine of the peptidoglycan precursor acting as carbonyl donor, and an amino group of the preexisting peptidoglycan acting as acceptor. Transpeptidation proceeds by conversion of the carbonyl donor to a short-lived acyl enzyme (with release of the COOH-terminal D-alanine) and subsequent attack on this acyl enzyme by the amino acceptor (with synthesis of a new interpeptide bond). The enzyme can become penicilloylated with a penicillin molecule instead of a D-alanine-terminated peptide, but the acyl enzyme thus formed is abnormally long-lived (3). Carboxypeptidation occurs when water is the acceptor.

More than 80 different β -lactamases have been identified and have been divided into three classes (A, B, and C). Most β -lactamases have been characterized as active-site serine enzymes belonging to classes A or C (3, 7, 8). Zinc-requiring β -lactamases constitute class B (9). One zinc DD-peptidase is also known; it catalyzes only carboxypeptidation reactions and is not a penicillin-binding protein (10). We now introduce three-dimensional structural data for a class A serine β -lactamase that will provide a new insight into the relatedness of serine members of the β -lactamase and DD-peptidase families.

The active-site serine DD-peptidase of *Streptomyces* R61 is excreted during growth in the form of a water-soluble PBP and has served as a model of the membrane-bound enzymes (2, 3). This PBP (37,400 daltons) has been crystallized, and its three-dimensional structure and penicillin binding site have been described at 2.8 Å resolution (11). Moreover, the structural gene has been cloned and sequenced (12).

In the β -lactamases of known sequence (4, 8), the active-site, penicillin-binding serine residue is flanked by a phenylalanine at the fourth position on its amino side and by a lysine at the third position on its carboxyl side, suggesting that these conserved phenylalanine and lysine residues are important for catalysis. The R61 DD-peptidase also possesses this important Phe-X-X-Ser-X-X-Lys sequence (Fig. 1). Moreover, when the comparison is broadened to a 25-amino-acid stretch that includes the active-site serine, the homology between the new sequence data for the R61 DD-peptidase and the *Bacillus licheniformis* (or *Bacillus cereus*) β -lactamase of class A (nine conserved amino acids), or between the R61 DD-peptidase and the *ampC* β -lactamase of class C (eight conserved amino acids), is found to be greater than the homology between the β -lactamases of class A and C (four or three conserved amino acids). The degree of homology, however, decreases when comparison extends away from the active site. For this reason, and because molecular mass differences between PBP's (40,000 to 90,000 daltons) and β -lactamases (30,000 daltons) are rather large, some authors believe evidence for common ancestry is weak (13).

J. A. Kelly, P. C. Moews, J. R. Knox, Department of Molecular and Cell Biology and Institute of Materials Science, University of Connecticut, Storrs, 06268.
O. Dideberg, P. Charlier, J. P. Wery, M. Libert, Service de Cristallographie, Institut de Physique, B5, Université de Liège, B-4000 Sart Tilman, Liège, Belgium.
C. Duez, Cl. Fraipont, B. Joris, J. Dusart, J. M. Frère, J. M. Ghuyesen, Service de Microbiologie, Institut de Chimie, B6, Université de Liège, B-4000 Sart Tilman, Liège, Belgium.

*To whom correspondence should be addressed.

Table I. Kinetic parameters of the interactions between the DD-peptidase of *Streptomyces* R61 and β -lactamase of *B. licheniformis* and various carbonyl donors.

Carbonyl donor*	<i>Streptomyces</i> R61 DD-peptidase				<i>B. licheniformis</i> β -lactamase		
	K_m (M)	k_{cat} (sec ⁻¹)	k_{+2}/K (M ⁻¹ sec ⁻¹)	k_{+3} (sec ⁻¹)	K_m (M)	k_{cat} (sec ⁻¹)	k_{+2}/K (M ⁻¹ sec ⁻¹)
Benzylpenicillin	1×10^{-8}	1.4×10^{-4}	14,000	1.4×10^{-4}	5×10^{-5}	2,600	53×10^6
Ac ₂ -L-Lys-D-Ala-D-Ala	1×10^{-2}	55	5,500	>55	No substrate activity		
Ac ₂ -L-Lys-D-Ala-D-Lac	4×10^{-2}	160	4,000†	>160	No substrate activity		

*H₂O is the nucleophilic acceptor of the transfer reactions. †Determined as described in (9).

enzymes may be another example of divergent evolution where structural changes required for their distinctive functions have appeared only in the relatively compact catalytic area. Deletions in the DD-peptidase sequence could have produced a smaller β -lactamase molecule, but the overall structural scaffolding of the penicillin-binding proteins has been maintained in spite of primary sequence changes. It may also be hypothesized that the primary response of soil bacteria, like *Streptomyces* spp., to exposure to β -lactam compounds produced by other microorganisms was to develop an excretion mechanism permitting release of a membrane-bound PBP. Subsequently, improvement of this mode of detoxification resulted in the transformation of this water-soluble penicillin-binding enzyme into a penicillin-hydrolyzing enzyme.

Detailed modeling of the DD-peptidase structure to 1.6 Å resolution and extension

of the β -lactamase structure with x-ray diffraction data to 2.0 Å may explain why β -lactam antibiotics are potent inhibitors of the target enzymes but are rapidly hydrolyzed substrates of the defensive β -lactamases.

REFERENCES AND NOTES

1. D. J. Tipper and J. L. Strominger, *Proc. Natl. Acad. Sci. U.S.A.* **54**, 1133 (1965).
2. J. M. Ghuyens, *Bacteriol. Rev.* **32**, 425 (1968).
3. J. M. Frère and B. Joris, *CRC Crit. Rev. Microbiol.* **1**, 299 (1985).
4. R. P. Ambler, *Philos. Trans. R. Soc. London Ser. B* **289**, 321 (1980).
5. B. G. Spratt, *J. Gen. Microbiol.* **129**, 1247 (1983).
6. J. M. Frère *et al.*, *FEBS Lett.* **70**, 257 (1976).
7. J. R. Knowles, *Acc. Chem. Res.* **18**, 97 (1985).
8. B. Jaurin and T. Grundstroem, *Proc. Natl. Acad. Sci. U.S.A.* **78**, 4897 (1981).
9. R. Bicknell, E. Emanuel, J. Gagnon, S. G. Waley, *Biochem. J.* **129**, 791 (1985); S. J. Cartwright and S. G. Waley, *Med. Res. Rev.* **3**, 341 (1983).
10. O. Dideberg *et al.*, *Nature (London)* **299**, 469 (1982); P. Charlier *et al.*, *Biochem J.* **219**, 763 (1984).
11. J. A. Kelly *et al.*, *Science* **218**, 479 (1982); J. A. Kelly *et al.*, *J. Biol. Chem.* **260**, 6449 (1985).
12. C. Duez, unpublished observation.
13. W. Keck, B. Glauner, U. Schwarz, J. K. Broome-Smith, B. G. Spratt, *Proc. Natl. Acad. Sci. U.S.A.* **82**, 1999 (1985).
14. J. R. Knox, J. A. Kelly, P. C. Moews, N. S. Murthy, *J. Mol. Biol.* **104**, 865 (1976); R. Aschaffenburg *et al.*, *ibid.* **120**, 447 (1978); J. Moulton *et al.*, *Biochem J.* **225**, 167 (1985); P. Charlier, O. Dideberg, J. M. Frère, P. C. Moews, J. R. Knox, *J. Mol. Biol.* **171**, 237 (1983); O. Dideberg *et al.*, *ibid.* **181**, 145 (1985); M. L. DeLucia, J. A. Kelly, M. M. Mangion, P. C. Moews, J. R. Knox, *Philos. Trans. R. Soc. London Ser. B* **289**, 374 (1980).
15. T. V. Williams, thesis, University of North Carolina, Chapel Hill (1982).
16. We acknowledge the NIH National Research Resource at the University of North Carolina, Chapel Hill, for providing GRINCH, and especially Michael Pique, who installed GRINCH at Storrs. Supported by grants from the Fonds de la Recherche Scientifique Medicale (Brussels, Belgium; contract No. 3.4507.83), the Belgian Government (Action concertée No. 79/84-II) and a Convention between the Region Wallonne, Continental Pharma and the University of Liège (to J.M.G.); from the Fonds de la Recherche Scientifique (No. 1.5.624.84 to O.D.); from NIH (10RRO1955-01 to AI-10925 and AI-16702 to J.R.K.), and from NATO (RG082.81 to O.D. and J.A.K.). Cl.F. is indebted to the Ministère de l'Emploi et du Travail, Belgium.

9 December 1985; accepted 31 January 1986

Tyr⁵²⁷ Is Phosphorylated in pp60^{c-src}: Implications for Regulation

JONATHAN A. COOPER, KATHLEEN L. GOULD, CHRISTINE A. CARTWRIGHT, TONY HUNTER

The Rous sarcoma virus oncogene product, pp60^{v-src}, transforms cultured fibroblasts but its corresponding proto-oncogene product, pp60^{c-src}, does not. Both proteins are known to be protein-tyrosine kinases. Published results suggest that the kinase activity of pp60^{c-src} is inhibited relative to that of pp60^{v-src}, due perhaps to phosphorylation of a tyrosine in pp60^{c-src} that is not phosphorylated in pp60^{v-src}. In this study, it was observed that the tyrosine phosphorylated in pp60^{c-src} is Tyr⁵²⁷, six residues from the COOH-terminus of the protein. The region of pp60^{c-src} from residue 515 to the COOH-terminus, including Tyr⁵²⁷, has been replaced with a different sequence in pp60^{v-src}. Thus, the increase in transforming ability and kinase activity that occurred in the genesis of pp60^{v-src} may have resulted from the loss of a tyrosine involved in negative regulation.

THE CELLULAR PROTEIN PP60^{c-src} IS the normal counterpart of the retroviral oncogene product, pp60^{v-src} (1). Fibroblasts cannot be transformed by pp60^{c-src} even when it is expressed at up to 15 times the normal level (2-4). In contrast, expression of pp60^{v-src} at an equivalent level to endogenous pp60^{c-src} induces transformation (4, 5). Both proteins are kinases that transfer phosphate to tyrosine residues in acceptor polypeptides, but when assayed in vitro with a variety of peptide substrates the specific activity of pp60^{c-src} is about 2 to 10 percent of the activity of pp60^{v-src} (6, 7). Comparison of their sequences shows that pp60^{c-src} and pp60^{v-src} differ in scattered point mutations and in their extreme COOH-termini: the last 19 residues of pp60^{c-src} are replaced by an unrelated se-

quence of 12 residues in pp60^{v-src} (8-10). Mutagenesis of c-src has shown that changes in either the body or the COOH-terminus of pp60^{c-src} can cause transformation (2). Significantly, replacement of the unique COOH-terminal tail of pp60^{c-src} by the pp60^{v-src} sequence or by an arbitrary sequence is sufficient for transformation (2, 3, 11). Thus the COOH-terminal tail, in the context of the pp60^{c-src} protein, apparently suppresses the transforming ability and protein kinase activity of pp60^{c-src}. How this occurs is unknown.

Phosphorylation of a tyrosine in pp60^{c-src} appears to be important for regulation. In the cell, both pp60^{v-src}s are phosphorylated at tyrosine and serine (1). Although the serines phosphorylated in pp60^{c-src} and pp60^{v-src} are the same, the major site of

tyrosine phosphorylation is different (12, 13). The v-src protein is phosphorylated at Tyr⁴¹⁶, and pp60^{c-src} is phosphorylated at an unknown tyrosine. In vitro, both pp60^{v-src}s can autophosphorylate, principally at Tyr⁴¹⁶ (12) and secondarily at one or more NH₂-terminal tyrosines (14). Thus, another protein kinase may phosphorylate the unknown tyrosine in pp60^{c-src}. Two pieces of evidence suggest that this phosphorylation may be inhibitory. Firstly, spontaneous mutations in c-src that activate its transforming ability encode proteins that are structurally very similar to pp60^{c-src} but are not phosphorylated at the c-src-specific tyrosine (6). Secondly, activation of pp60^{c-src} can occur after cell lysis because of the action of phosphatases that remove phosphate from the unique tyrosine (15). Here we report that pp60^{c-src} is phosphorylated at Tyr⁵²⁷, which lies in the COOH-terminal sequence that appears to suppress transformation. Phosphorylation of Tyr⁵²⁷ is probably critical for the regulation of pp60^{c-src} kinase activity and transforming potential.

The tyrosine phosphorylation site in pp60^{c-src} is known to lie in the COOH-terminal 26,000 daltons (12). For more precise mapping, we analyzed tryptic and chymotryptic peptides obtained from ³²P_i-labeled pp60^{c-src}. Trypsin-digestion of pp60^{c-src} from ³²P_i-labeled mouse cells that express high levels of chicken pp60^{c-src}

J. A. Cooper, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
K. L. Gould, C. A. Cartwright, T. Hunter, Molecular Biology and Virology Laboratory, The Salk Institute, San Diego, CA 92138.